Essex LLC Buys 1,634 Shares of Pfizer Inc. $PFE

Essex LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.7% during the 2nd quarter, Holdings Channel.com reports. The fund owned 63,209 shares of the biopharmaceutical company’s stock after purchasing an additional 1,634 shares during the quarter. Essex LLC’s holdings in Pfizer were worth $1,532,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. GKV Capital Management Co. Inc. purchased a new stake in Pfizer during the 1st quarter valued at $27,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer in the first quarter valued at about $28,000. North Capital Inc. purchased a new position in shares of Pfizer in the first quarter valued at about $28,000. WPG Advisers LLC bought a new position in shares of Pfizer during the first quarter valued at about $35,000. Finally, Horizon Financial Services LLC purchased a new stake in shares of Pfizer during the first quarter worth about $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley cut their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday. Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, UBS Group restated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $28.35.

Pfizer Stock Performance

Shares of PFE stock opened at $24.53 on Wednesday. The company’s fifty day moving average price is $24.88 and its 200-day moving average price is $24.12. The stock has a market cap of $139.44 billion, a PE ratio of 13.05, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.82.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.